TALL-1
1
Discover top-quality products tailored for scientific and medical research. Request a personalized quote today
to enhance your projects.
TALL-1 is a lymphocyte-like T cell leukemia cell line that originated from the bone marrow of a 28-year-old man in the advanced leukemic stage of lymphosarcoma. Possessing distinct T-cell properties, these cells notably lack the Epstein-Barr virus and its genetic material. Growing in suspension as single cells, they exhibit both spherical and rod-shaped forms. TALL-1 cells demonstrate a population doubling time of 50-70 hours and exhibit positive immunostaining for CD2, cyCD3, CD4, CD7, and CD8, while displaying negative staining for CD13, CD19, and CD34.
Why choose TALL-1 from AcceGen?
TALL-1 from AcceGen is available to researchers for its superior quality and viability. Our cells undergo rigorous quality control, ensuring sterility through daily monitoring and PCR testing. They are free from various pathogens, including EBV, HBV, HCV, HIV-1, HIV-2, HTLV-1/2, MLV, and SMRV. Additionally, advanced cryopreservation techniques guarantee optimal preservation.
| Product Code | TALL 1; TALL1; T-ALL-1; T-ALL 1; T-ALL1; T-cell Acute Lymphoblastic Leukemia-1 |
| Species | Human |
| Cat.No | ABL-TC0657 |
| Product Category | Tumor Cell Lines |
| Size/Quantity | 1 vial |
| Cell Type | Lymphocyte-like |
| Shipping Info | Dry Ice |
| Growth Conditions | 37 ℃, 5% CO2 |
| Source Organ | Bone Marrow |
| Disease | Acute Lymphoblastic Leukemia |
| Biosafety Level | 1 |
| Storage | Liquid Nitrogen |
| Product Type | Human Leukemia Cell Lines |
When you publish your research, please cite our product as “AcceGen Biotech Cat.# XXX-0000”. In return, we’ll give you a $100 coupon. Simply click here and submit your paper’s PubMed ID (PMID).
FOR RESEARCH USE ONLY
The TALL-1 cell line offers a valuable resource for researchers delving into the features and chemosensitivity of human leukemic T-cells. Its application extends to exploring pivotal elements in the advancement and progression of lymphoid malignancies, particularly T-ALL, shedding light on underlying mechanisms. Additionally, it aids in identifying essential genes in the molecular pathogenesis of human T-ALL, thereby offering insights into potential strategies for targeted therapeutic interventions.
